Medtronic 3F无支架主动脉瓣置换的中期结局
单中心、单术者连续226例主动脉瓣病患者植入Medtronic 3F无支架瓣膜,其中30例用于Bentall手术,随访完整率100%、平均63±2.4个月;孤立主动脉瓣置换早期死亡率为1.7%,10年生存率93%,因结构衰败的免于再手术率5年100%、10年96%。
要点
- 孤立主动脉瓣置换早期死亡率1.7%,随访97%患者心功能为NYHA I或II级
- 因结构衰败的免于再手术率5年100%、10年96%,10年免于感染性心内膜炎97%
- 出院与末次随访平均主动脉跨瓣压差分别为11.5 mmHg和10.4 mmHg
核心结论
- 3F瓣膜是第三代无支架主动脉瓣,耐久性已获验证,血流动力学表现随时间的推移保持良好。
- 3F尤其适用于预计存在患者-人工瓣膜不匹配的病例。
研究设计与样本
- 2007年3月至2015年8月,单中心单术者连续226例主动脉瓣病患者植入Medtronic 3F瓣膜。
- 30例瓣膜被置入带瓣管道行Bentall手术,瓣膜尺寸21至29,手术年龄74.17±8.58岁。
- 平均logistic EuroSCORE为9.73±6.00,51.3%患者接受同期手术。
- 孤立瓣膜置换的平均体外循环时间92±17分钟,主动脉阻断时间73±11分钟。
- 随访完整率100%,平均63±2.4个月(范围6-138个月)。
主要发现
- 孤立主动脉瓣置换早期死亡率为1.7%。
- 晚期全因死亡59例(25.3%),其中心源性死亡15例(6.6%),10年生存率93%。
- 随访时97%患者为纽约心脏协会(NYHA)心功能I或II级。
- 因结构衰败的免于再手术率5年100%、10年96%,10年免于感染性心内膜炎为97%。
- 超声心动图测得的平均主动脉跨瓣压差出院时为11.5 mmHg,末次随访时为10.4 mmHg。
临床怎么用
- 对主动脉瓣病变患者,3F无支架瓣膜可获得良好的中期耐久性与血流动力学,尤适用于预计患者-人工瓣膜不匹配者。
局限性
- 为单中心、单术者连续病例系列,无对照组,结论的外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study evaluated the early and intermediate-term clinical and hemodynamic results after implant of the Medtronic 3F (Minneapolis, MN) stentless aortic valve. METHODS: Between March 2007 and August 2015, 226 consecutive patients affected by aortic valve disease received a 3F valve at our unit by a single surgeon. The valve in 30 patients was included in a tubular prosthesis for a Bentall procedure. Size ranged between 21 and 29, age at operation was 74.17 ± 8.58 years, mean logistic European System for Cardiac Operative Risk Evaluation was 9.73 ± 6.00, and 51.3% of patients received a concomitant procedure. For isolated valve replacement, mean extracorporeal circulation time was 92 ± 17 minutes, and cross-clamp time was 73 ± 11 minutes. Follow-up was 100% complete and was a mean of 63 ± 2.4 months (range, 6-138 months). Primary end points were early and late mortality, freedom from endocarditis, freedom from structural valve deterioration, and freedom from valve-related reoperation. RESULTS: Early mortality after isolated aortic valve replacement was 1.7%. Of the 59 (25.3%) late overall deaths, 15 (6.6%) were cardiac-related, and survival rate was 93% at 10 years. At follow-up, 97% of patients were in New York Heart Association class I or II. Actuarial freedom from reoperation due to structural deterioration was 100% at 5 years and 96% at 10 years. Freedom from endocarditis at 10 years was 97%. Mean aortic pressure gradient measured by echocardiography was 11.5 mm Hg at hospital discharge and 10.4 mm Hg at the last follow-up. CONCLUSIONS: The 3F valve is a user-friendly third-generation stentless aortic prosthesis with proven durability and remarkable hemodynamic performance preserved over time. The 3F is particularly useful in cases of expected patient/prosthesis mismatch.
引用
- Stefanelli G, Pirro F, Longo M, et al. Intermediate-Term Outcomes After Aortic Valve Replacement With the Medtronic 3F Stentless Prosthesis. Ann Thorac Surg. 2020. PMID: 33045206. doi:10.1016/j.athoracsur.2020.07.053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。